KURA ONCOLOGY INC's ticker is KURA and the CUSIP is 50127T109. A total of 122 filers reported holding KURA ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $195,000 | -91.6% | 10,434 | -87.3% | 0.01% | -91.9% |
| Q1 2021 | $2,316,000 | +77.6% | 81,934 | +105.2% | 0.09% | +45.8% |
| Q4 2020 | $1,304,000 | +15.5% | 39,934 | +8.4% | 0.06% | +1.7% |
| Q3 2020 | $1,129,000 | +48.6% | 36,834 | -21.0% | 0.06% | +38.1% |
| Q2 2020 | $760,000 | +57.7% | 46,634 | -3.7% | 0.04% | +23.5% |
| Q1 2020 | $482,000 | -17.3% | 48,434 | +14.1% | 0.03% | +3.0% |
| Q4 2019 | $583,000 | +3.6% | 42,434 | +14.4% | 0.03% | -2.9% |
| Q3 2019 | $563,000 | -25.7% | 37,100 | -3.6% | 0.03% | -26.1% |
| Q2 2019 | $758,000 | +18.6% | 38,500 | 0.0% | 0.05% | +15.0% |
| Q1 2019 | $639,000 | +51.8% | 38,500 | +28.3% | 0.04% | +42.9% |
| Q4 2018 | $421,000 | -19.8% | 30,000 | 0.0% | 0.03% | -9.7% |
| Q3 2018 | $525,000 | -3.8% | 30,000 | 0.0% | 0.03% | -6.1% |
| Q2 2018 | $546,000 | -3.0% | 30,000 | 0.0% | 0.03% | -8.3% |
| Q1 2018 | $563,000 | +8.9% | 30,000 | -11.3% | 0.04% | +9.1% |
| Q4 2017 | $517,000 | – | 33,805 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,849,947 | $16,871,517 | 9.37% |
| Prosight Management, LP | 1,932,456 | $17,623,999 | 5.58% |
| ACUTA CAPITAL PARTNERS, LLC | 702,093 | $6,403,088 | 4.29% |
| ALETHEA CAPITAL MANAGEMENT, LLC | 350,445 | $3,196,058 | 3.93% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,335,845 | $66,902,906 | 3.62% |
| Affinity Asset Advisors, LLC | 856,535 | $7,811,599 | 2.20% |
| TCG Crossover Management, LLC | 1,423,642 | $12,983,615 | 1.91% |
| EcoR1 Capital, LLC | 5,806,871 | $52,958,664 | 1.79% |
| BVF INC/IL | 6,730,983 | $61,386,565 | 1.66% |
| DAFNA Capital Management LLC | 550,784 | $5,023,150 | 1.56% |